Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Argentina has been growing steadily in recent years, driven by various factors such as increasing demand for organ transplantation, rising prevalence of autoimmune diseases, and growing geriatric population.
Customer preferences: Patients in Argentina prefer generic drugs due to their affordability and accessibility. The high cost of branded immunosuppressants has led to the widespread use of generic versions, which has further fueled the growth of the market. Additionally, patients prefer drugs that have fewer side effects and are more effective in treating their condition.
Trends in the market: One of the major trends in the Immunosuppressants market in Argentina is the increasing use of biologics. Biologics are becoming popular due to their efficacy in treating autoimmune diseases and organ transplantation. The market is also witnessing a shift towards targeted therapies, which offer a more personalized approach to treatment. Another trend is the growing demand for biosimilars, which are expected to drive down the cost of treatment and increase accessibility.
Local special circumstances: Argentina has a well-established healthcare system, which provides universal coverage to its citizens. The government has implemented various policies to provide affordable healthcare to all, which has led to increased demand for immunosuppressants. Additionally, the country has a high prevalence of autoimmune diseases, which has further boosted the demand for these drugs.
Underlying macroeconomic factors: Argentina has been facing economic challenges in recent years, which has impacted the healthcare sector. The devaluation of the Argentine peso has led to a rise in the cost of imported drugs, which has affected the availability and affordability of immunosuppressants. The country is also facing a shortage of healthcare professionals, which has led to delays in diagnosis and treatment. However, the government has implemented various measures to address these challenges and improve the healthcare system.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
